Manning & Napier Group's SNY Position Overview
Manning & Napier Group (via Manning & Napier Advisors LLC) currently holds 1.19 M shares of Sanofi (SNY) worth $57.54 M, representing 0.81% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 52 quarters.
Based on 13F filings since 2013, Manning & Napier Group has maintained a long-term strategic position in SNY, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2014, adding 2.61 M shares. Largest reduction occurred in Q1 2015, reducing 2.93 M shares.
Analysis based on 13F filings available since 2013 Q2
Manning & Napier Group's Sanofi (SNY) Holding Value Over Time
Track share changes against reported price movement
Quarterly Sanofi (SNY) Trades by Manning & Napier Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +1.19 M | Add 728134.75% | 1.19 M | $48.18 |
| Q4 2025 | -195,839 | Reduce 99.92% | 164 | $48.74 |
| Q3 2025 | +31,003 | Add 18.79% | 196,003 | $47.20 |
| Q2 2025 | -107,998 | Reduce 39.56% | 165,000 | $48.31 |
| Q1 2025 | -7,883 | Reduce 2.81% | 272,998 | $55.46 |
| Q4 2024 | +12,688 | Add 4.73% | 280,881 | $48.23 |
| Q3 2024 | -14,677 | Reduce 5.19% | 268,193 | $57.63 |
| Q2 2024 | +138,749 | Add 96.27% | 282,870 | $48.52 |
| Q1 2024 | -14,392 | Reduce 9.08% | 144,121 | $48.60 |
| Q4 2023 | -228 | Reduce 0.14% | 158,513 | $49.73 |
| Q3 2023 | -716 | Reduce 0.45% | 158,741 | $53.64 |
| Q2 2023 | +6,380 | Add 4.17% | 159,457 | $53.90 |
| Q1 2023 | -3,445 | Reduce 2.20% | 153,077 | $54.42 |
| Q4 2022 | -4,409 | Reduce 2.74% | 156,522 | $48.43 |
| Q3 2022 | -269 | Reduce 0.17% | 160,931 | $38.02 |
| Q2 2022 | -1,815 | Reduce 1.11% | 161,200 | $50.02 |
| Q1 2022 | -22,840 | Reduce 12.29% | 163,015 | $51.34 |
| Q4 2021 | -1,177 | Reduce 0.63% | 185,855 | $50.09 |
| Q3 2021 | -940 | Reduce 0.50% | 187,032 | $48.20 |
| Q2 2021 | +187,972 | New Buy | 187,972 | $52.66 |
| Q2 2019 | -247,817 | Sold Out | 247,817 | $44.28 |
| Q1 2019 | +4,706 | Add 1.94% | 247,817 | $44.28 |
| Q4 2018 | +3,166 | Add 1.32% | 243,111 | $43.41 |
| Q3 2018 | +3,857 | Add 1.63% | 239,945 | $44.67 |
| Q2 2018 | -11,502 | Reduce 4.65% | 236,088 | $40.01 |
| Q1 2018 | +8,421 | Add 3.52% | 247,590 | $40.08 |
| Q4 2017 | +239,170 | Add 0.00% | 239,169 | $42.99 |
| Q3 2017 | -1,237 | Reduce 0.51% | 243,175 | $49.78 |
| Q2 2017 | +130 | Add 0.05% | 244,412 | $47.91 |
| Q1 2017 | +18,094 | Add 8.00% | 244,282 | $45.24 |
| Q4 2016 | -58,629 | Reduce 20.58% | 226,188 | $40.44 |
| Q3 2016 | -3,593 | Reduce 1.25% | 284,817 | $38.19 |
| Q2 2016 | +12,905 | Add 4.68% | 288,410 | $41.84 |
| Q1 2016 | -6,412 | Reduce 2.27% | 275,505 | $40.16 |
| Q4 2015 | -2.54 M | Reduce 90.00% | 281,917 | $42.65 |
| Q3 2015 | -60,276 | Reduce 2.09% | 2.82 M | $47.47 |
| Q2 2015 | +379,867 | Add 15.20% | 2.88 M | $49.53 |
| Q1 2015 | -2.93 M | Reduce 54.00% | 2.5 M | $49.44 |
| Q4 2014 | +408,674 | Add 8.13% | 5.43 M | $45.61 |
| Q3 2014 | +2.06 M | Add 69.69% | 5.02 M | $56.43 |
| Q2 2014 | +38,098 | Add 1.30% | 2.96 M | $53.17 |
| Q1 2014 | +2.61 M | Add 836.86% | 2.92 M | $52.28 |
| Q4 2013 | -11,307 | Reduce 3.50% | 312,008 | $53.62 |
| Q3 2013 | +7,476 | Add 2.37% | 323,315 | $50.62 |
| Q2 2013 | +315,839 | Add 0.00% | 315,839 | $51.50 |
Manning & Napier Group's Sanofi Investment FAQs
Manning & Napier Group first purchased Sanofi (SNY) in Q2 2013, acquiring 315,839 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Manning & Napier Group has held Sanofi (SNY) for 52 quarters since Q2 2013.
Manning & Napier Group's largest addition to Sanofi (SNY) was in Q1 2014, adding 2,923,087 shares worth $152.82 M.
According to the latest 13F filing for Q1 2026, Manning & Napier Group's firm, Manning & Napier Advisors LLC, owns 1,194,305 shares of Sanofi (SNY), valued at approximately $57.54 M.
As of the Q1 2026 filing, Sanofi (SNY) represents approximately 0.81% of Manning & Napier Group's publicly disclosed stock portfolio, making it one of their key holdings.
Manning & Napier Group's peak holding in Sanofi (SNY) was 5,433,472 shares, as reported at the end of Q4 2014.